

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Jonathan A. Terrett

SERIAL NO.: 10/510,508

EXAMINER: Unassigned

DATE FILED: October 7, 2004

ART UNIT: Unassigned

FOR: PROTEIN INVOLVED IN CANCER

EXPRESS MAIL NO.: EV 247182828 US

DATE OF DEPOSIT: APRIL 5, 2005

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BA** through **CF** listed on the attached Form PTO-1449. However, with respect to References **BA** & **BC**, please note that due to the size of these references (9,787 & 532 pages respectively), a CD containing references WO 01/22920 and WO 00/55633 in Adobe .pdf format is enclosed in place of a printed copy. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David A. Jackson', is written over a horizontal line.

David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
201-487-5800

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-038PCT/US
	SERIAL NO.	10/510,508
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan Alexander Terrett
	FILING DATE	October 7, 2004
	GROUP	Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	WO 01/22920A2	4/5/01	PCT			
	BB	WO 98/29431	7/9/98	PCT			
	BC	WO 00/55633A3	9/21/00	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Payne, JA, et al., Primary Structure, Functional Expression, and Chromosomal Localization of the Bumetanide-sensitive Na-K-Cl Cotransporter in Human Colon*, 1995, J. Biol. Chem., 270(30): Pgs. 17977-17985.
CB	Vibat, CRT, et al., Quantitation of Na ⁺ -K ⁺ -2Cl ⁻ Cotransport Splice Variants in Human Tissues Using Kinetic Polymerase Chain Reaction, 2001, Anal. Biochem., 298(2): Pgs. 218-230.
CC	Dolganov, GM, et al, A Novel Method of Gene Transcript Profiling in Airway Biopsy Homogenates Reveals Increased Expression of a Na ⁺ -K ⁺ -Cl ⁻ Cotransporter (NKCC1) in Asthmatic Subjects, 2001, Genome Res., 11(9): Pgs. 1473-1483.
CD	Shumaker H, et al., CFTR upregulates the expression of the basolateral Na ⁺ -K ⁺ -2Cl ⁻ co-transporter in cultured pancreatic duct cells, 1999, Amer. Physiol. Soc. 277: Pgs C1100-C1110
CE	Majid, A. et al., Expression of the Na ⁺ -K ⁺ -2Cl ⁻ cotransporter in α and β cells isolated from the rat pancreas, 2001, Pfluegers Archiv. Eur. J. Physiol. 442: Pgs. 570-576.
CF	Adam, PJ, et al., Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer*, 2001, J. Biol. Chem. 278: Pgs. 6482-6489.

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.